291 results on '"Tsushima T"'
Search Results
2. Measurement and comparison of individual external doses of high-school students living in Japan, France, Poland and Belarus -- the 'D-shuttle' project --
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
5. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
6. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
7. 1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)
8. 446TiP Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
9. 1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma
10. P-95 Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
11. PD-013 Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)
12. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
13. New method for quantitative assessment of airway calibre using a stereovision fibreoptic bronchoscope
14. SAFETY AND EFFICACY OF PROTON-BEAM RADIATION THERAPY FOR PATIENTS WITH LOCALLY RECURRENT RECTAL CANCER
15. EFFICACY AND SAFETY OF CHEMORADIOTHERAPY FOR PATIENTS WITH LOCOREGIONAL LYMPH NODE RECURRENCE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
16. CORRELATION BETWEEN THE EFFECTS OF FIRST-LINE CHEMOTHERAPY AND SURVIVAL TIME FROM SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
17. P-356 phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study
18. P-69 Efficacy and safety of S-1 following gemcitabine with cisplatin for biliary tract cancer
19. Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
20. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer
21. PF635 SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS
22. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study
23. Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
24. Carbon content dependence of the spin reorientation in Er2Fe17Cx
25. 1772P - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
26. A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410)
27. Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors
28. A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
29. Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
30. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE)
31. Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy
32. Faraday Rotation in [Co.sup.3+]-Substituted Magnetic Garnets
33. 1111P - Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer
34. 511P - Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study
35. 394P A self-controlled trial of prophylactic topical application of vitamin K1 cream for cetuximab-related skin rash
36. 165P Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102
37. 191P Comparison of neoadjuvant chemotherapy followed by surgery (NAC) with adjuvant chemotherapy following surgery (ADJ), and NAC with definitive chemoradiotherapy for locally advanced esophageal cancer patients
38. Solubilization of insulin binding and degrading activity from guinea pig kidneys
39. Immunoprecipitation of 125I-insulin crosslinked receptor
40. First report of Coleus blumei viroid 5 infection in vegetatively propagated clonal coleus cv. ‘Aurora black cherry’ in Japan
41. PD-017 A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)
42. First report of Dahlia latent viroid and Potato spindle tuber viroid mixed‐infection in commercial ornamental dahlia in Japan
43. LBA17 - Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors
44. 516P - A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410)
45. 639P - A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
46. 638P - Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
47. Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors
48. Clinicopathological Features and Outcomes of Gastric Cancer Patients with Pulmonary Lymphangitis Carcinomatosa
49. 668P - Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy
50. Outcome of Anti-Egfr Antibody Therapy in Metastatic Colorectal Cancer with Low-Frequency Kras Mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.